» Download Public Reports
About 300 reports
- Company report
- December 2012
- 5 pages
... That can lead to cirrhosis and liver cancer. The development of nafld/nash is associated with the pathophysiological process of insulin resistance in patients that are overweight and/or diabetic. Nafld ...
January 2013
... Flml) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The company has a proprietary pipeline of niche specialty pharmaceutical products ...
April 2013
... Health will drive forward public health knowledge, which is a key issue for all governments." The french-german advanced translational drug discovery center is a unique project of public- private ...
May 2013
... That dicobalt edetate only be given when the patient is tending to lose or has lost consciousness. Distamine penicillamine a disease modifying antirheumatic drug (dmard) used for the treatment of rheumatoid ...
November 2012
... And epigenetic status Epilepsy and other neurologic disorders Cardiovascular screening and function childhood cancer Multidisciplinary multidimensional aspects of sensory input, learning and behavior ...
December 2012
... Of generic 21 vancomycin (van) products approved for use in humans, based on experiments in a 22 neutropenic mouse thigh infection model. However, other animal models may be more 23 appropriate to decipher ...
April 2013
... Of a pathologic oxygen supply dependency remains contro- versial. Study objective: to evaluate the relationship between oxygen delivery (do2) and oxygen consumption (vo2) during severe sepsis and to compare ...
March 2013
... Are seen first and foremost as businesses, in other words, as players seeking to make a profit: 90% (-1) Of the french and 96% of doctors believe that the aim of drug companies is to make a profit ...
January 2013
... If parallel changes in do2 and vo2 seen in a patient with critical illness reflect pathologic supply dependency, or just the normal cardiovascular re- sponse to acute changes in oxygen demand in patients ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 1 000 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
